The global partnership will leverage Paige’s technology to reduce unnecessary treatment, support better patient stratification, and help standardize the measurement of residual cancer burden
Paige, a leader in next-generation AI technology, and the Breast International Group, a leading international non-profit organization dedicated to breast cancer research, announced a new partnership to conduct collaborative research aimed at improving breast cancer diagnosis, treatment, and patient outcomes.
By integrating Paige’s innovative AI into our clinical research, we can strengthen our understanding of tumor biology, enhance trial design, and accelerate progress…
By combining BIG’s clinical expertise, global academic clinical trials, and comprehensive patient datasets with Paige’s advanced AI capabilities, the partnership aims to generate new insights that enhance biomarker detection, predict response to treatment, and enable the use of AI-driven tools for optimizing and personalizing therapy to make high-quality care more accessible. AI-powered diagnostics offer the potential to improve testing turnaround time, speed up clinical decision-making, all while sparing both cost and tissue and allow clinicians to focus only on the tests most needed for individualized patient care. The collaboration will focus on addressing areas of unmet clinical need in breast cancer, including rare breast cancer subtypes.
Health Technology Insights: Maxor Rebrands as VytlOne to Reflect Pharmacy Innovation
As part of the initiative, Paige and BIG will evaluate the performance of OmniScreen, an AI application that simulates a panel of 1,600 clinically significant cancer biomarkers within 505 genes by analyzing H&E-stained images. The primary objective of this evaluation is to identify mutation-associated phenotypes in breast cancer. The research will also explore additional applications of Paige’s technology to help standardize the measurement of residual cancer burden, support more effective patient stratification, and reduce unnecessary treatment. By embedding AI earlier in the diagnostic and research workflows, the partners aim to support more informed clinical decisions and accelerate the delivery of personalized care for people with breast cancer.
“This partnership reflects our belief that AI is no longer just a future promise, it is a present-day solution to some of the most complex challenges in cancer,” said Razik Yousfi, CEO and CTO of Paige. “By combining BIG’s world-class clinical research expertise in breast cancer with Paige’s AI technology, we will accelerate the translation of insights into clinical impact, with the common goal of transforming breast cancer care.”
The collaboration builds on BIG’s legacy of groundbreaking, cooperative clinical research by incorporating advanced digital pathology tools into its scientific portfolio.
“We are excited to collaborate with Paige on this ambitious research effort,” said David Cameron, Chair of the Breast International Group and Professor of Oncology at Edinburgh University, UK. “Our shared mission is to improve the lives of people with breast cancer. By integrating Paige’s innovative AI into our clinical research, we can strengthen our understanding of tumor biology, enhance trial design, and accelerate progress toward more tailored and effective treatments.”
Health Technology Insights: TYBR Health Gets FDA OK for B3 GEL to Protect Healing Tissue
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
